cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Century Therapeutics Inc
1 watching
Current Price
$4.65
$-0.11
(-2.31%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
270.56M
52-Week High
52-Week High
15.375
52-Week Low
52-Week Low
4.335
Average Volume
Average Volume
0.11M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization270.56M
icon52-Week High15.375
icon52-Week Low4.335
iconAverage Volume0.11M
iconDividend Yield--
iconP/E Ratio--
What does the Century Therapeutics Inc do?
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company s lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Read More
How much money does Century Therapeutics Inc make?
News & Events about Century Therapeutics Inc.
Globe Newswire
1day ago
CNTY-101 is the first cell therapy product candidate engineered with six precision gene edits including a CD19-CAR, Allo-Evasiontechnology, IL-15 cytokine support and a safety switch ELiPSE-1 trial to test multi-dosing strategy for CAR iNK enabled by Allo-Evasionedits designed to resist 3 major ...
Zolmax
2 months ago
ADMA Biologics (NASDAQ:ADMA Get Rating) and Century Therapeutics (NASDAQ:IPSC Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, ...
Globe Newswire
3 months ago
- Preclinical data support next generation platform for iPSC-derived NK cells with multiple gene edits to improve persistence and anti-tumor efficacy - - iPSC-derived CAR gamma delta T cells shown to effectively control solid tumors as monotherapy and in combination with a therapeutic antibody - - ...
Frequently Asked Questions
Frequently Asked Questions
What is Century Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Century Therapeutics Inc shares?
plus_minus_icon
How can I buy Century Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Century Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Century Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Century Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Century Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Century Therapeutics Inc?
plus_minus_icon
What percentage is Century Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Century Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$4.65
$-0.11
(-2.31%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00